Relapse after allogeneic hematopoietic cell transplantation (HCT) is the leading cause of death in patients with acute myeloid leukemia (AML) entering HCT with poor-risk features ^1-3 . When HCT does produce prolonged relapse-free survival, it commonly reflects graft-versus-leukemia effects mediated by donor T cells reactive with antigens on leukemic cells ⁴ . As graft T cells have not been selected for leukemia specificity and frequently recognize proteins expressed by many normal host tissues, graft-versus-leukemia effects are often accompanied by morbidity and mortality from graft-versus-host disease ⁵ . Thus, AML relapse risk might be more effectively reduced with T cells expressing receptors (TCRs) that target selected AML antigens ⁶ . We therefore isolated a high-affinity Wilms' Tumor Antigen 1-specific TCR (TCR _C4 ) from HLA-A2 ⁺ normal donor repertoires, inserted TCR _C4 into Epstein-Bar virus-specific donor CD8 ⁺ T cells (T _TCR-C4 ) to minimize graft-versus-host disease risk and enhance transferred T cell survival ^7,8 , and infused these cells prophylactically post-HCT into 12 patients ( NCT01640301 ). Relapse-free survival was 100% at a median of 44 months following infusion, while a concurrent comparative group of 88 patients with similar risk AML had 54% relapse-free survival (P = 0.002). T _TCR-C4 maintained TCR _C4 expression, persisted long-term and were polyfunctional. This strategy appears promising for preventing AML recurrence in individuals at increased risk of post-HCT relapse.